EPLAW PATENT BLOG

UK – Electromagnetic Geoservices v Petroleum Geo-Services & ors

Posted: April 21st, 2016

Electromagnetic Geoservices ASA v Petroleum Geo-Services & others, UK, High Court (Patents Court), Birss J, 19 April 2016 This judgement arose in the context of a patent dispute concerning European Patent (UK) 0256019. The trial took 11 days in the Patents Court. The parties settled the proceedings shortly before judgement. As a result ordinarily no […]

READ MORE

EPO – The EPO’s power to appoint oral proceedings in the Hague not subject to review by the EBA

Posted: April 11th, 2016

EPO, R 13/14, EBA, decision of 15 January 2016 – Borealis Technology OY, not to be published in OJ EPO The EPC 2000 implemented the BEST (Bringing Search and Examination Together) project. Since then the departments of first instance of the EPO rendering decisions are no longer located only in Munich but also in the […]

READ MORE

EPO – TBA finds a substantial procedural violation because of excessive length of grant proceedings – appeal fee reimbursed

Posted: April 1st, 2016

EPO, T 823/11, TBA 3.5.07, decision of 21 December 2015 – Managing patient care /CAREFUSION The application was filed in the US as an international application on 15 May 1996 and entered the European phase on 15 December 1997. The supplementary European search report was issued on 18 February 1999. After three communications, the Examining […]

READ MORE

UK – Napp v Dr Reddy’s and Sandoz

Posted: March 22nd, 2016

Napp Pharmaceutical Holdings Ltd. v (1) Dr Reddy’s Laboratories (UK) Ltd. (2) Sandoz Ltd., High Court of England and Wales (Arnold J), London, UK, 7 March 2016, Neutral Citation Number:  [2016] EWHC 493 (Pat) On 7 March 2016, Arnold J considered whether it was appropriate to hear applications for the trial of a preliminary issue […]

READ MORE

UK – Eli Lilly v. Janssen Sciences Ireland

Posted: March 18th, 2016

Eli Lilly and Company v Janssen Sciences Ireland UC (formally Janssen Alzheimer Immunotherapy), High Court of Justice of England and Wales, Patents Court (Rose J), London UK, 18 February 2016, Neutral Citation Number: [2016] EWHC 313 (Pat) On 18 February 2016, Rose J. refused Janssen’s application for a stay of the invalidity and declaration of […]

READ MORE

UK – Fujifilm Kyowa Biologics v. AbbVie

Posted: March 17th, 2016

Fujifilm Kyowa Biologics Co., Ltd. v AbbVie Biotechnology Ltd., High Court of England and Wales (Carr J), London, UK, 1 March 2016, Neutral Citation Number: [2016] EWHC 425 (Pat) The English High Court has confirmed that it has jurisdiction to grant a declaration that a dosage regime for a biosimilar product would have been anticipated […]

READ MORE

UK – Celltrion v. Biogen Idec

Posted: February 25th, 2016

Celltrion Inc v (1) Biogen Idec Inc. (2) F. Hoffmann-La-Roche AG & (3) Genentech Inc., High Court of Justice of England and Wales, Patents Court (Carr J.), London UK, 22 January 2016, Neutral Citation Number: [2016] EWHC 188 (Pat)  On 22 January 2016, Carr J granted the Claimant’s application for an order that its claim […]

READ MORE

UK – Regeneron v. Kymab and Novo Nordisk

Posted: February 16th, 2016

Regeneron Pharmaceuticals Inc v Kymab Limited and Novo Nordisk A/S, High Court of England and Wales (Carr J), London, UK, 1 February 2016, Neutral Citation Number: [2016] EWHC 87 (Pat).  On 3 February 2016 the Patents Court (Carr J) held that the disputed claims of two of Regeneron’s patents relating to transgenic mice used for […]

READ MORE

ES – Astrazeneca v. Laboratorios Alter

Posted: February 15th, 2016

On 21st December 2015, The Supreme Court handed down a decision in the case of AstraZeneca AB & others v Laboratorios Alter and & others (EDJ 2015/244058). AstraZeneca had filed an action against several generic companies for infringement of an SPC for the product quetaipina: The SPC’s basic patent was EP 228. EP 228 was […]

READ MORE